Antidiabetic medicines consumption and cost for payer and patients during pandemia - the case for Bulgaria

Zornitsa Mitkova[1], Miglena Krasimirova[1], Maria Dimitrova[1], Guenka Petrova[1]

[1]Department of Organization and Economy of Pharmacy; Faculty of Pharmacy; Medical University-Sofia

1 INTRODUCTION

❖ The global prevalence of type II diabetes has increased, particularly in low- and middle-income countries (LMICs). Therapy cost varies significantly and is correlated with the economic progress of the countries

❖ The prevalence of type II diabetes is highest between the ages of 60 and 74, accounting for around 500,000 people (6.5% of the population) in Bulgaria (2)

2 OBJECTIVE

The pandemic deteriorates medicines supply and access to patients therefore influencing the cost of therapy. We aimed to analyse the changes in antidiabetic medicines consumption and cost for patients and payers.

3 METHODS

❖ This is a retrospective, observational analysis, performed during the period 2020- 2022.

❖ Evaluates 23 International Nonproprietary Names (INNs) included in the Positive Drug List (PDL).

❖ Reimbursed medicines and cost for payer were collected from officially available sources (NHIF and NCPRMP).

❖ Utilization was calculated per INN in DDD/1000inh/day.

❖ Reimbursement expenditures during pandemic period (2020 – 2022) are calculated in absolute and relative units.

❖ Patient co-payment was also calculated as cost per patient.

4 RESULTS

2020-2022 NHIF cost per INN

Utilization comparison of monoproducts during 2020-2022

Utilization comparison of fixed doses combinations during 2020-2022

2020-2022 Patients cost per INN

5 CONCLUSION

Patients with type II diabetes and society experienced a heavy cost burden for medicines therapy during the pandemic period. Their spending is approximately evenly divided. Patients must not be burdened with excessive costs; instead, new policy measures aimed at ensuring consistent supply and lowering copayment are required.

6 REFERENCES

1. Seuring, T., Archangelidi, O. &Suhrcke, M. TheEconomicCostsofType 2 Diabetes: A GlobalSystematicReview. PharmacoEconomics 33, 811–831 (2015)
2. Tachkov K, Mitov K, Koleva Y, Mitkova Z, Kamusheva M, Dimitrova M, Petkova V, Savova A, Doneva M, Tcarukciev D, Valov V, Angelova G, Manova M, Petrova G. Life expectancy and survival analysis of patients with diabetes compared to the non-diabetic population in Bulgaria. PLoS One. 2020 May 11;15(5):e0232815.